FDA Approves Vascepa to Reduce Cardiovascular Risk – American College of Cardiology

On Dec. 13, Vascepa (icosapent ethyl) became the first U.S. Food and Drug Administration (FDA)-approved medication for reducing cardiovascular risk beyond cholesterol lowering therapy in high-risk patients approved for treatment. The drug was approved specifically “as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction,…

Read the full article here

Related Articles